# A phase I single-arm, multicenter pilot study aimed at validating y-OHPdG as a biomarker and testing the effects of Polyphenon E on its levels in patients with cirrhosis

> **NIH NIH N01** · NORTHWESTERN UNIVERSITY · 2022 · $142,069

## Abstract

Hepatocellular carcinoma (HCC) is a lethal cancer with rising incidence and rates. In 2014, about 33,000     HCC diagnoses were expected, and the incidence is increasing among the most rapidly of any cancer, with an age-adjusted annual increase of 3.7% and 2.9% in men and women, respectively (3%). Tragically, HCC has a dismal 5-year survival rate of 18%. Hepatocarcinogenesis begins with changes in the liver architerure as reflected by various degrees of cirrhosis.

## Key facts

- **NIH application ID:** 10551085
- **Project number:** 261201200035I-P00005-26100013-1
- **Recipient organization:** NORTHWESTERN UNIVERSITY
- **Principal Investigator:** Seema Khan
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $142,069
- **Award type:** —
- **Project period:** 2020-11-06 → 2023-09-22

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10551085

## Citation

> US National Institutes of Health, RePORTER application 10551085, A phase I single-arm, multicenter pilot study aimed at validating y-OHPdG as a biomarker and testing the effects of Polyphenon E on its levels in patients with cirrhosis (261201200035I-P00005-26100013-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10551085. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*